GSK and Vir seek emergency use of COVID-19 therapy in United States

GSK and Vir Biotechnology have filed an application to U.S. regulators for emergency use authorization of their antibody therapy to treat early-stage COVID-19 infections, the drugmakers said on Friday.

Earlier this month, London-listed GSK and U.S.-based Vir found their experimental treatment, VIR-7831, reduced the risk of hospitalization and deaths among patients by 85%, based on interim data from a study. The application is to treat adults and adolescents of over 12 yeas of age and weighing at least 40 kilograms that have mild-to-moderate COVID-19 and are at risk of being hospitalised due to severe illness which could also lead to death.